Our results highlight the efficacy of SO in inhibiting lactic acid production by esophageal cancer cells and thus show that the use of an LDHA inhibitor can be considered in the design of adjuvant therapy for esophageal cancer patients. This evidence concerns the gene LDHA and esophageal cancer.